Is GLP-1 receptor agonist therapy safe for patients with intraductal papillary mucinous neoplasm?
Swiss Medical Weekly · 2025
DOI: 10.57187/s.4850 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Swiss Medical Weekly, 2025. Verfasst von Melissa Lagger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Fribourg Cantonal Hospital, Villars-sur-Glâne, Switzerland. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Pancreatic Neoplasms, Pancreatic Intraductal Neoplasms, Hypoglycemic Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists are increasingly used in the management of obesity and diabetes. Their potential risks, however, particularly regarding pancreatitis and pancreatic cancer, remain contentious. Despite numerous studies and meta-analyses indicating no significant correlation between GLP-1 RA therapy and the incidence of acute pancreatitis or pancreatic cancer, gaps in the literature persist regarding their effects in patients with frequent pancreatic conditions, such as intraductal papillary mucinous neoplasms, a disease with potential for malignant transformation. Further rigorous clinical studies addressing the safety of GLP-1 receptor agonists in patients with intraductal papillary mucinous neoplasms should be conducted to understand the potential risks and benefits, establish clear guidelines for clinical practice and ultimately ensure the safety of these medications in this potentially vulnerable patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Fribourg Cantonal Hospital, Villars-sur-Glâne, Switzerland.
- University of Fribourg, Fribourg, Switzerland.
- Hirslanden Clinics Geneva, Geneva, Switzerland.
- Department of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland.
ORCID-Profile: Melissa Lagger, Pouya Irmanesh, Michel Adamina, Leo Buhler
Zitieren
APA
Lagger, M., Irmanesh, P., Frossard, J. L., Adamina, M., & Buhler, L. (2025). Is GLP-1 receptor agonist therapy safe for patients with intraductal papillary mucinous neoplasm?. Swiss Medical Weekly. https://doi.org/10.57187/s.4850
Vancouver
Lagger M, Irmanesh P, Frossard JL, Adamina M, Buhler L. Is GLP-1 receptor agonist therapy safe for patients with intraductal papillary mucinous neoplasm?. Swiss Medical Weekly. 2025. doi:10.57187/s.4850
BibTeX
@article{Lagger2025,
author = {Lagger, Melissa and Irmanesh, Pouya and Frossard, Jean-Louis and Adamina, Michel and Buhler, Leo},
title = {Is GLP-1 receptor agonist therapy safe for patients with intraductal papillary mucinous neoplasm?},
journal = {Swiss Medical Weekly},
year = {2025},
doi = {10.57187/s.4850}
}
EUVIMED